http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3024444-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_116c851e729089df9a427027272fa290
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2086
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4409
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4409
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
filingDate 2014-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e9bd80a489d255a79bead1bab4daeab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b89f7065c33446f91b997668f1b44d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c91321b0cda079361b17505dea9c007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18c52ce92bb1bf838005eb8298c38ec4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fed1697029811b30610d753fba6c47a
publicationDate 2016-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-3024444-A1
titleOfInvention Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
abstract The present invention relates to an oral pharmaceutical fixed dose composition in a form of a dispersible tablet for use in the treatment of tuberculosis, said oral pharmaceutical composition comprising: a) granules comprising isoniazid and at least one intragranular excipient, b) granulescomprising rifapentine and at least one intragranular excipient, and c) at least one extragranular excipient, and to its process of preparation.
priorityDate 2013-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID136122663
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226414451
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395910
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID136145328
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396820
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395911
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11954184
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID136963266
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID134601
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393830
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226408288
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226441773
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394849
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135925261
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396819
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3423265
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2242
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6251
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394850
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412184
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23667548
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393819
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45051774
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395773
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226426585
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393829
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11177
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226426586
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412182
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14985
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10149043
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135403821
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11178
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393724
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5362585
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23623894
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45051773
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226441774
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15324
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393345
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3767
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395861
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395774
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393946
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID443953
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87057646
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54676860
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398735
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID311215644
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395359

Total number of triples: 78.